Beranda › Neuroblastoma › Arkansas › Little Rock
Uji klinis Neuroblastoma di Little Rock, AR
6 studi untuk Neuroblastoma mencari peserta di lokasi sekitar Little Rock (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Menerima pesertaFase 3
- Arkansas Children's Hospital, Little Rock
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Menerima pesertaFase 2
- Arkansas Children's Hospital, Little Rock
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Menerima pesertaFase 1/2
- Arkansas Children's Hospital, Little Rock
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Menerima pesertaFase 2
- Arkansas Children's Hospital, Little Rock
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Menerima pesertaFase 3
- Arkansas Children's Hospital, Little Rock
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Menerima pesertaFase 2
- Arkansas Children's Hospital, Little Rock
Uji klinis Neuroblastoma di kota lain
- Boston, MA13 studi
- Washington, DC11 studi
- New York City, NY10 studi
- Memphis, TN9 studi
- Philadelphia, PA9 studi
- Dallas, TX9 studi
- St. Louis, MO9 studi
- Aurora, CO8 studi
- Hartford, CT8 studi
- Minneapolis, MN8 studi
- Birmingham, AL8 studi
- Atlanta, GA7 studi
Studi lain di Little Rock
- Skizofrenia19 studi
- Kanker (semua jenis)14 studi
- Gangguan Depresi Mayor14 studi
- Leukemia Mieloid Akut13 studi
- Kanker Paru Non-Sel Kecil13 studi
- Obesitas11 studi
- Kanker Endometrium10 studi
- Diabetes Tipe 210 studi
- Depresi10 studi
- Kanker Kandung Kemih9 studi
- Kanker Paru9 studi
- Gagal Jantung9 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.